695 related articles for article (PubMed ID: 32497804)
41. Phospholipid Metabolism Is Associated with Time to HIV Rebound upon Treatment Interruption.
Giron LB; Papasavvas E; Yin X; Goldman AR; Tang HY; Palmer CS; Landay AL; Li JZ; Koethe JR; Mounzer K; Kostman JR; Liu Q; Montaner LJ; Abdel-Mohsen M
mBio; 2021 Feb; 12(1):. PubMed ID: 33622719
[TBL] [Abstract][Full Text] [Related]
42. Cells producing residual viremia during antiretroviral treatment appear to contribute to rebound viremia following interruption of treatment.
Aamer HA; McClure J; Ko D; Maenza J; Collier AC; Coombs RW; Mullins JI; Frenkel LM
PLoS Pathog; 2020 Aug; 16(8):e1008791. PubMed ID: 32841299
[TBL] [Abstract][Full Text] [Related]
43. Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation.
Aziz N; Sokoloff A; Kornak J; Leva NV; Mendiola ML; Levison J; Feakins C; Shannon M; Cohan D
BJOG; 2013 Nov; 120(12):1534-47. PubMed ID: 23924192
[TBL] [Abstract][Full Text] [Related]
44. Reduction in HIV community viral loads following the implementation of a "Treatment as Prevention" strategy over 2 years at a population-level among men who have sex with men in Hangzhou, China.
He L; Yang J; Ma Q; Zhang J; Xu Y; Xia Y; Chen W; Wang H; Zheng J; Jiang J; Luo Y; Xu K; Zhang X; Xia S; Pan X
BMC Infect Dis; 2018 Feb; 18(1):62. PubMed ID: 29390979
[TBL] [Abstract][Full Text] [Related]
45. Structural Determinants of Antiretroviral Therapy Use, HIV Care Attendance, and Viral Suppression among Adolescents and Young Adults Living with HIV.
Kahana SY; Jenkins RA; Bruce D; Fernandez MI; Hightow-Weidman LB; Bauermeister JA;
PLoS One; 2016; 11(4):e0151106. PubMed ID: 27035905
[TBL] [Abstract][Full Text] [Related]
46. Receipt of opioid agonist treatment halves the risk of HIV-1 RNA viral load rebound through improved ART adherence for HIV-infected women who use illicit drugs.
Adams JW; Marshall BDL; Mohd Salleh NA; Barrios R; Nolan S; Milloy MJ
Drug Alcohol Depend; 2020 Jan; 206():107670. PubMed ID: 31711873
[TBL] [Abstract][Full Text] [Related]
47. Short-term outcomes of rapid initiation of antiretroviral therapy among HIV-positive patients: real-world experience from a single-centre retrospective cohort in Taiwan.
Huang YC; Sun HY; Chuang YC; Huang YS; Lin KY; Huang SH; Chen GJ; Luo YZ; Wu PY; Liu WC; Hung CC; Chang SC
BMJ Open; 2019 Sep; 9(9):e033246. PubMed ID: 31542770
[TBL] [Abstract][Full Text] [Related]
48. Viral load suppression after intensive adherence counselling among adult people living with HIV at Kiswa health centre, Kampala: a retrospective cohort study. Secondary data analysis.
Nakaye C; Mukiza N; Mawanda D; Kataike H; Kaganzi H; Ahimbisibwe GM; Businge GB; Kyambadde RC; Nakalega R
AIDS Res Ther; 2023 Mar; 20(1):18. PubMed ID: 36998004
[TBL] [Abstract][Full Text] [Related]
49. Viral suppression and viral rebound among young adults living with HIV in Canada.
Palmer A; Gabler K; Rachlis B; Ding E; Chia J; Bacani N; Bayoumi AM; Closson K; Klein M; Cooper C; Burchell A; Walmsley S; Kaida A; Hogg R;
Medicine (Baltimore); 2018 Jun; 97(22):e10562. PubMed ID: 29851775
[TBL] [Abstract][Full Text] [Related]
50. Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy.
Suaysod R; Ngo-Giang-Huong N; Salvadori N; Cressey TR; Kanjanavanit S; Techakunakorn P; Krikajornkitti S; Srirojana S; Laomanit L; Chalermpantmetagul S; Lallemant M; Le Cœur S; McIntosh K; Traisathit P; Jourdain G
Clin Infect Dis; 2015 Jul; 61(1):95-101. PubMed ID: 25838288
[TBL] [Abstract][Full Text] [Related]
51. HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa.
Havlir DV; Balzer LB; Charlebois ED; Clark TD; Kwarisiima D; Ayieko J; Kabami J; Sang N; Liegler T; Chamie G; Camlin CS; Jain V; Kadede K; Atukunda M; Ruel T; Shade SB; Ssemmondo E; Byonanebye DM; Mwangwa F; Owaraganise A; Olilo W; Black D; Snyman K; Burger R; Getahun M; Achando J; Awuonda B; Nakato H; Kironde J; Okiror S; Thirumurthy H; Koss C; Brown L; Marquez C; Schwab J; Lavoy G; Plenty A; Mugoma Wafula E; Omanya P; Chen YH; Rooney JF; Bacon M; van der Laan M; Cohen CR; Bukusi E; Kamya MR; Petersen M
N Engl J Med; 2019 Jul; 381(3):219-229. PubMed ID: 31314966
[TBL] [Abstract][Full Text] [Related]
52. Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?
Bansi LK; Benzie AA; Phillips AN; Portsmouth S; Hill T; Leen C; Schwenk A; Johnson M; Anderson J; Gilson R; Easterbrook P; Gazzard B; Fisher M; Orkin C; Porter K; Pillay D; Taylor GP; Walsh JC; Sabin CA;
AIDS; 2008 Jan; 22(3):349-56. PubMed ID: 18195561
[TBL] [Abstract][Full Text] [Related]
53. A Markov model for the effects of virological failure on HIV/AIDS progression in tuberculosis co-infected patients receiving antiretroviral therapy in a rural clinic in northern South Africa.
Shoko C; Chikobvu D; Bessong PO
S Afr Med J; 2020 Mar; 110(4):313-319. PubMed ID: 32657744
[TBL] [Abstract][Full Text] [Related]
54. Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir.
Calin R; Hamimi C; Lambert-Niclot S; Carcelain G; Bellet J; Assoumou L; Tubiana R; Calvez V; Dudoit Y; Costagliola D; Autran B; Katlama C;
AIDS; 2016 Mar; 30(5):761-9. PubMed ID: 26730568
[TBL] [Abstract][Full Text] [Related]
55. Two-fold increase in the HIV viral load suppression rate along with decreased incidence over six years in Ndhiwa sub-county, Kenya.
Conan N; Badawi M; Chihana ML; Wanjala S; Kingwara L; Mambula C; Ngugi C; Okomo G; Opollo V; Salumu L; Nesbitt R; Szumilin E; Huerga H
Trop Med Int Health; 2021 Dec; 26(12):1609-1615. PubMed ID: 34637172
[TBL] [Abstract][Full Text] [Related]
56. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy.
Scott Sutton S; Magagnoli J; Hardin JW
Pharmacotherapy; 2016 Apr; 36(4):385-401. PubMed ID: 26923931
[TBL] [Abstract][Full Text] [Related]
57. Virological rebound after suppression on highly active antiretroviral therapy.
Mocroft A; Ruiz L; Reiss P; Ledergerber B; Katlama C; Lazzarin A; Goebel FD; Phillips AN; Clotet B; Lundgren JD;
AIDS; 2003 Aug; 17(12):1741-51. PubMed ID: 12891060
[TBL] [Abstract][Full Text] [Related]
58. Factors associated with viral non-suppression among adolescents living with HIV in Cambodia: a cross-sectional study.
Chhim K; Mburu G; Tuot S; Sopha R; Khol V; Chhoun P; Yi S
AIDS Res Ther; 2018 Nov; 15(1):20. PubMed ID: 30445984
[TBL] [Abstract][Full Text] [Related]
59. Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure.
Shroufi A; Van Cutsem G; Cambiano V; Bansi-Matharu L; Duncan K; Murphy RA; Maman D; Phillips A
AIDS; 2019 Aug; 33(10):1635-1644. PubMed ID: 31305331
[TBL] [Abstract][Full Text] [Related]
60. Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.
Kearney MF; Wiegand A; Shao W; Coffin JM; Mellors JW; Lederman M; Gandhi RT; Keele BF; Li JZ
J Virol; 2016 Feb; 90(3):1369-76. PubMed ID: 26581989
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
